What question did this study set out to answer?

Synthesize recent clinical evidence regarding the efficacy and safety of approved antiviral therapies for influenza, with a focus on special high-risk populations and emerging resistance.

December 1, 2021Seminars in Respiratory and Critical Care Medicine

Antiviral Treatments for Influenza

View Full Paper

Ask AI

Bookmark

Why the study?

Several new drugs have become available to treat influenza, but little information remains available regarding their efficacy and safety in special populations.

What are the efficacy and safety profiles of currently available antiviral treatments for influenza?

Design

Review of literature

Authors

EPEmanuele PalombaUniversity of Milan VCValeria CastelliFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico GRGiulia RenisiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Discussion

Member takes

Implication

Limited data in critically ill and chronic respiratory patients warrant caution; leaves open need for targeted efficacy and resistance trials.

Key Points

Synthesize recent clinical evidence regarding the efficacy and safety of approved antiviral therapies for influenza, with a focus on special high-risk populations and emerging resistance.
Conducted a narrative literature review of recent clinical data evaluating currently approved antiviral agents for influenza across global healthcare markets.
Assessed drug safety and efficacy profiles across patient groups, specifically reviewing evidence in critically ill individuals and those with chronic respiratory disease.
Confirmed established clinical efficacy and safety profiles for neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and the cap-dependent endonuclease inhibitor baloxavir marboxil.
Identified a persistent scarcity of clinical efficacy and safety data in high-risk special populations, including critically ill patients and individuals with underlying chronic respiratory disease.
Reported growing concerns regarding the emergence of influenza strains exhibiting reduced susceptibility or complete resistance to current antiviral medications.

Structured PICO

What are the efficacy and safety profiles of currently available antiviral treatments for influenza?

Population

Patients with influenza, including special populations such as critically ill patients and patients with a history of chronic respiratory disease

Intervention

Antiviral treatments including neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and cap-dependent endonuclease inhibitor baloxavir marboxil

Outcome

Efficacy and safety of drugs

This review highlights the efficacy and safety of current influenza antivirals while noting the lack of data in special populations and the concerning emergence of resistant viral strains.

Limitations

Little information available about special populations such as critically ill patients and patients with a history of chronic respiratory disease

Cite This Study

Palomba et al. (2021) studied this question.

synapsesocial.com/papers/69de6d91681d8c8a46e93dd1 https://doi.org/10.1055/s-0041-1733830

View Full Paper

Ask AI

Bookmark

Implication

Limited data in critically ill and chronic respiratory patients warrant caution; leaves open need for targeted efficacy and resistance trials.

Antiviral Treatments for Influenza

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Antiviral Treatments for Influenza

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider